First-in-human, phase I study of AK109, an anti-VEGFR2 antibody, in patients (pts) with advanced or metastatic solid tumors.

	First-in-human, phase I study of AK109, an anti-VEGFR2 antibody, in patients (pts) with advanced or metastatic solid tumors.
	Xu, Nong ; Zheng, Yulong ; Zhong, Haijun ; Zhao, Fuyou ; Zhou, Huan ; Mao, Chenyu ; Lv, Wangxia ; Yuan, Meiqin ; Qian, Jiong ; Jiang, Haiping
刊名	JOURNAL OF CLINICAL ONCOLOGY
	2022-06-01
卷号	40
ISSN号	0732-183X
资助项目	Akeso Biopharma, Inc.
WOS研究方向	Oncology
语种	英语
出版者	LIPPINCOTT WILLIAMS & WILKINS
WOS记录号	WOS:000863680300914
资助机构	Akeso Biopharma, Inc.
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/129921]
专题	中国科学院合肥物质科学研究院
作者单位	1.Akeso Biopharma Inc, Zhongshan, Peoples R China 2.Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Peoples R China 3.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Beijing, Peoples R China 4.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou, Peoples R China 5.Bengbu Med Coll, Affiliated Hosp 1, Bengbu, Peoples R China 6.Zhejiang Univ, Affiliated Hosp 1, Dept Oncol, Sch Med, Hangzhou, Peoples R China 7.Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Xu, Nong,Zheng, Yulong,Zhong, Haijun,et al. First-in-human, phase I study of AK109, an anti-VEGFR2 antibody, in patients (pts) with advanced or metastatic solid tumors.[J]. JOURNAL OF CLINICAL ONCOLOGY,2022,40.
APA	Xu, Nong.,Zheng, Yulong.,Zhong, Haijun.,Zhao, Fuyou.,Zhou, Huan.,...&Xia, Yu.(2022).First-in-human, phase I study of AK109, an anti-VEGFR2 antibody, in patients (pts) with advanced or metastatic solid tumors..JOURNAL OF CLINICAL ONCOLOGY,40.
MLA	Xu, Nong,et al."First-in-human, phase I study of AK109, an anti-VEGFR2 antibody, in patients (pts) with advanced or metastatic solid tumors.".JOURNAL OF CLINICAL ONCOLOGY 40(2022).